Translational Medicine
Open Access

Molecular & Immunological Department, Chinese PLA General Hospital, China

Publications

• Short Communication   
  Translational Medicine 2015: Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An early phase IIa trial report - Wei-Dong Han - Chinese PLA General Hospital
  Author(s): Wei-Dong Han*
  
  Patients with relapsed or refractory Non-Hodgkin lymphoma (NHL) make sure a dismal prediction. Chimeric antigen receptor (CAR) modified T cells targeting CD20 have shown activity in clinical test phase I clinical trial for patients with advanced B-cell lymphomas. We performed a phase IIa trial to further assess the security and efficacy of administering autologous anti-CD20 CAR T (CART-20) cells to patients with refractory or relapsed CD20+ Bcell lymphoma. Eleven (11) patients comprising one with previous auto-HSCT and one primary cutaneous B-cell lymphomas were enrolled. Seven (7) patients experienced cytoreductive chemotherapy for tumor debulking and lymphocyte depletion before T cell potions. CART-20 cells were infused into patients at doses of 2.8 to 14.6×106 cells/kg. The general objective response rate was 9 of 11 (81%), with six complete remissions (CR) and three partial .. View More»
  DOI: 10.35248/2161-1025.20.10.204

  Abstract HTML PDF